Posters
« Back
ADP-Glo™ Kinase Profiling Systems for Targeted and Flexible Kinase Inhibitor Profiling
EP23511
Poster Title: ADP-Glo™ Kinase Profiling Systems for Targeted and Flexible Kinase Inhibitor Profiling
Submitted on 09 Oct 2015
Author(s): Hicham Zegzouti, Jacquelyn Hennek, Juliano Alves, and Said Goueli
Affiliations: Promega Corporation
Poster Views: 2,321
View poster »


Poster Information
Abstract: Drug safety is of paramount importance in the pharmaceutical industry indicating that minimal side effects constitute a major requirement in drug development. Therefore, novel drug candidates need to be profiled against various liability targets, including a broad panel of kinases to provide a better understanding of off-target activities. Potentially, profiling can also identify new targets that may lead to novel therapeutic indications. A universal, robust and affordable technology is desirable to assess selectivity and potency of drug candidates against multiple classes of kinases. The luminescent ADP-Glo™ kinase assay is a universal platform that measures kinase activity by quantifying the amount of ADP produced during the enzymatic reaction. We have tested the utility of this platform with 174 optimized Kinase Enzyme Systems (KES) spanning different families of the human kinome. Here we present standardized Kinase Profiling Systems for simple kinase inhibitor profiling studies. The Kinase Profiling Systems are a set of kinases organized by families and presented in easy to use multiwell strips. Each strip contains eight enzymes each with their corresponding substrates, and standardized for optimal kinase activity for inhibitor profiling. Using the profiling strips we easily generated selectivity profiles, identifying compound promiscuity towards members of a single kinase subfamily or different subfamilies of the kinome. The ADP-Glo™ KES platforms now address the needs of basic kinase characterization, kinase screening, mode of action (MOA) studies and profiling in an affordable manner using one assay format.Summary: Drug safety is of paramount importance in the pharmaceutical industry indicating that minimal side effects constitute a major requirement in drug development. Therefore, novel drug candidates need to be profiled against various liability targets, including a broad panel of kinases to provide a better understanding of off-target activities. Potentially, profiling can also identify new targets that may lead to novel therapeutic indications.References: Hicham Zegzouti, Jacquelyn Hennek, Juliano Alves, and Said Goueli
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Assessing & fulfilling the need for teaching on Radiology requesting for fifth year medical students
Dr Hina Khan, Dr Rathinasabapathy Rajmohan, Mr Ahmed Hawash

A review of unexpected findings on 18F-FDG PET-CT (PET-CT) in the extracranial head and neck. A local institutional experience.
Mohsin Hussein, Catalin Ivan, Yvette Griffin.

A RARE CASE OF MYOFIBROBLASTOMA OF OROPHARNX
Muneeba Nasir, Kashif Naeem

Donkey Milk Based Products: An innovative Cottage Enterprise for Enhancing Farmers Income
Anuradha Bhardwaj, Yash Pal, Varij Nayan, R.A. Legha, Hema Tripathi, B.N. Tripathi

Interesting case of right iliac fossa pain in a UK patient
Dr K Shahzad, Mr I Peristerakis, Dr M Pitt, Dr S Mathew